This review outlines the pharmacotherapeutic management of acute decompensated heart failure, emphasizing the tailored use of diuretics, vasodilators, and inotropes based on Forrester hemodynamic subsets.
Answers are grounded in this paper and cite their sources.
Highlights need for better ADHF strategies in critical care; leaves open optimal pharmacotherapy approaches pending higher-level evidence.
Five million people in the United States are living with heart failure and this number continues to climb.1 Patients with this chronic disease commonly present to the hospital in what is known as acute decompensated heart failure (ADHF). The prognosis of ADHF is poor, with in-hospital mortality ranging from 4% to 7%, 60- to 90-day mortality ranging from 7% to 11%, and 60- to 90-day rehospitalization rates ranging from 25% to 30%.2A patient experiencing ADHF typically displays shortness of breath (due to low cardiac output), pulmonary edema, or a combination of the two. Patients are classified into 1 of 4 Forrester hemodynamic subsets based on the presenting clinical syndrome (see Figure).3 This classification system helps health care providers develop appropriate treatment plans using medications such as diuretics, vasodilators, and inotropic agents (Table 1).4–10 Once hemodynamic stabilization is achieved, initiating or resuming long-term pharmacotherapies is essential to reducing readmission and mortality.11 In this Drug Update column, we provide relevant clinical pearls for the optimal use of diuretic, vasodilator, and inotropic therapies, guided by an understanding of the Forrester hemodynamic subsets, to improve fluid status and end-organ perfusion.Brain natriuretic peptide is released into circulation in response to stretching of the ventricles. Elevated levels indicate volume overload (ie, the patient is “wet”) and can therefore help diagnose ADHF. Patients in Forrester hemodynamic subsets II and IV with suspected volume overload are typically treated with intravenous (IV) diuretics in addition to dietary sodium and fluid restriction. Although not routinely recommended, invasive hemodynamic monitoring with a pulmonary artery catheter is used when clinical assessment or consideration for advanced therapies is warranted.12 Complications associated with invasive monitoring include the risks of arrhythmias, arterial rupture, thrombosis, and infection. Invasive and noninvasive hemodynamic monitoring using central venous pressure, pulmonary capillary wedge pressure, urine output, and signs and symptoms of congestion (eg, pulmonary edema, jugular venous pressure, peripheral edema) help the health care team plan a course of action. Although goals may vary among health care teams, common target values for patients with ADHF are a pulmonary capillary wedge pressure of 15 to 18 mm Hg and a central venous pressure of less than 8 mm Hg. Values above these ranges indicate an elevated preload, and patients with such values would symptomatically benefit from diuresis.13Patients with ADHF presenting with suspected fluid overload should be treated quickly with IV loop diuretics to reduce morbidity.11 Loop diuretics such as furosemide, torsemide, and bumetanide are preferred over other diuretics (eg, thiazide diuretics, potassium-sparing diuretics) because of their pronounced effect on urine output.4,5,14 Patients who had been taking loop diuretic therapy at home should receive an IV dose equal to or exceeding their chronic oral daily dose.11 See Table 2 for proper dose conversion for loop diuretics.4,5,14Although data comparing the loop diuretics are limited, furosemide is the most commonly used. Because 50% of furosemide is systemically absorbed after oral administration,4 providers can essentially double the patient’s oral home dose by ordering the same dose for IV administration. On the other hand, doses changed from IV to oral must be halved to achieve an equivalent conversion. Torsemide and bumetanide have better oral bioavailability than furosemide and do not require dose conversion when changing between oral and IV routes.Whether loop diuretic therapy is more effective in resolving symptoms, increasing diuresis, and improving outcomes when administered via continuous IV infusion or via intermittent IV bolus remains unknown. The most well-known trial to date, the DOSE-AHF (Determining Optimal Dose and Duration of Diuretic Treatment in People With Acute Heart Failure) trial, compared both strategies but did not find any significant efficacy or safety differences between the 2 strategies.15 The choice of treatment strategy remains contingent on provider preference, failure of the initial strategy, and renal function.Additionally, the DOSE-AHF trial compared low-dose (home dose) and high-dose (2.5 times the home dose) strategies. At 72 hours, the results indicated favorable global symptom assessment outcomes using the high-dose strategy. However, more patients receiving the high-dose strategy than the low-dose strategy experienced increased serum creatinine levels.15Monitoring clinical signs and symptoms is imperative in any patient undergoing aggressive diuresis. Loop diuretics have potent effects on urine output, which can impact fluid and electrolyte status. Excessive diuresis must be avoided because of the risk of hypokalemia, hyperglycemia, hyperuricemia, or more serious events like hypotension, acute kidney injury, and metabolic alkalosis. Further, electrolytes such as sodium, potassium, chloride, and magnesium are lost in the urine and should be replaced as necessary.4,5,14A rare but serious adverse effect of loop diuretics is ototoxicity. Ototoxicity is related to the peak serum drug concentration and the rate of infusion and can lead to permanent deafness. Ethacrynic acid is a loop diuretic rarely used because of its high ototoxicity risk, but it offers an alternative for patients with a severe sulfa allergy. It is the only loop diuretic that does not contain a sulfonamide group in its chemical structure.4,5,14Signs of diuretic response include resolution of edema and dyspnea. However, resistance to loop diuretics often occurs before optimal response is achieved. Strategies such as combination therapy, dose escalation, and alternative drug delivery may be considered to optimize diuresis. Chlorothiazide and metolazone are common thiazide diuretics used in conjunction with loop diuretics. The thiazide diuretic is given 30 minutes prior to the loop diuretic to produce synergistic effects. Chlorothiazide is available as an injection, an oral suspension, and a tablet.16 It is ineffective in patients with poor renal function (creatinine clearance < 30 mL/min) because of its inability to achieve adequate concentration within the distal tubules of the kidney. Metolazone is available only in tablet form but is the most effective thiazide diuretic in patients with poor renal function.17Following the addition of a thiazide diuretic, physicians generally prefer to add an aldosterone antagonist such as spironolactone or eplerenone. These medications competitively bind receptors at the aldosterone-dependent sodium-potassium exchange sites in the distal tubules, leading to increased excretion of sodium, chloride, and water, and retention of potassium and hydrogen. Both medications have been shown to have mortality benefit in patients with heart failure–reduced ejection fraction (HFrEF), defined as the clinical diagnosis of heart failure with a left ventricular ejection fraction of 40% or less.11 During therapy with aldosterone antagonists, the serum potassium level should be monitored to prevent hyperkalemia. Eplerenone is more selective for the aldosterone receptor and has a lower incidence of endocrine-related adverse effects but is contraindicated in patients with a creatinine clearance of 30 mL/min or less and a serum potassium level greater than 5.5 mEq/L.18 Spironolactone is typically preferred over eplerenone because of its low cost and fewer drug interactions.18,19Patients with ADHF and heart failure– preserved ejection fraction (left ventricular ejection fraction greater than 40%) tend to be older, female, and more likely to present with severe hypertension than those with ADHF and HFrEF.20 Hypertension can be caused by elevated filling pressures and/or left ventricular afterload. These patients typically present as “wet” in Forrester hemodynamic subset II or IV. Although routine use of vasodilators has not been shown to improve outcomes, successful vasodilator use may allow providers to avoid adjunct inotropic therapy while improving symptoms of pulmonary edema and hypertension.21Intravenous nitroglycerin, nitroprusside, and nesiritide all have venous vasodilator properties that help reduce preload. Adding a vasodilator while awaiting the onset of action of a diuretic may allow for acute relief of pulmonary edema. Intravenous nitroglycerin is the most common vasodilative agent used because it heavily favors venous vasodilation, which in turn reduces preload. Arterial vasodilation is not typically seen unless high doses are achieved (eg, 100 μg/min). Like loop diuretics, IV nitroglycerin must be protected from light. It is supplied in a glass bottle rather than a plastic bag because of drug adsorption issues. A potential concern with nitroglycerin is tachyphylaxis, which can occur with prolonged and high dosing of this drug.22 Nitroglycerin’s short half-life (1–4 minutes) can be viewed as a double-edged sword. On one hand, if the patient becomes symptomatically hypotensive, discontinuing this agent will likely resolve the issue. On the other hand, patients may experience rebound hypertension upon abrupt nitroglycerin discontinuation.6Nitroprusside and nesiritide are alternative IV vasodilators providing greater arterial effects than IV nitroglycerin. Nitroprusside provides balanced arterial and venous vasodilation. Although the incidence of cyanide toxicity with nitroprusside is unknown, its use is limited because of concerns from published case reports.23 Alternative vasodilators should be considered if prolonged infusions are needed or in patients with renal failure.23 Additionally, blood pressure stabilization is difficult with nitroprusside because small changes in dose can have dramatic effects on blood pressure. Nesiritide causes both arterial and venous dilation but also possesses natriuretic properties beneficial for patients with fluid overload.8 Natriuresis reduces fluid volume by promoting urinary sodium excretion, which causes osmotic forces to pull water out of the body. Its substantial cost relative to IV nitroglycerin restricts its use.The use of inotropic agents is confined to situations in which clinical evidence suggests the patient is exhibiting end-organ dysfunction or hypoperfusion (ie, the patient is “cold”; Forrester hemodynamic subset III or IV). Routine use of these agents is not recommended because of increased mortality and lack of survival benefit.24 These agents should be used only in the short term to improve the pumping ability of the left ventricle and prevent further end-organ damage. Inotrope administration should target a cardiac index of greater than 2.2 L/min per square meter. In patients in Forrester hemodynamic subset IV, initiating vasodilator therapy first may avert the need for adjunct inotropic therapy. In patients in Forrester hemodynamic subset III, it is important to verify satisfactory filling pressures by monitoring pulmonary capillary wedge pressure or central venous pressure and ensure the patient has not undergone excessive diuresis. Inotropic agents are ideally used when the heart has adequate venous return but lacks the pumping power needed for adequate perfusion to end organs and tissues.24Patients with heart failure classified as stage D by the American College of Cardiology and American Heart Association are considered to have refractory or end-stage heart failure and may be candidates for advanced treatment strategies such as continuous inotropic support, mechanical circulatory support, or cardiac transplantation.11 In patients with ADHF, short-term (< 72 hours) inotropic support is used to preserve end-organ damage when severe systolic dysfunction exists in conjunction with hypotension and poor cardiac output.24 In either circumstance, dobutamine and milrinone are the inotropic agents of choice. Both agents provide positive inotropic and lusitropic effects, but only dobutamine provides a positive chronotropic effect. Dobutamine is therefore preferable in patients with hypotension, whereas milrinone is preferable in patients receiving concomitant β-blocker therapy.Milrinone is a phosphodiesterase inhibitor that increases cardiac output and reduces systemic vascular resistance.10 Administration of a bolus dose prior to infusion may be omitted because of the potential for profound hypotension. Hypotension that develops upon initiation may be attributed to an aggressive initial infusion rate (> 0.375 μg/kg per minute). Dose reduction may resolve the issue and preclude the need for vasopressor support. Unfortunately, because of milrinone’s 1-hour half-life, vasopressor support may be needed temporarily. Its half-life may be prolonged in patients with renal impairment (creatinine clearance < 50 mL/min) and reducing the rate of initial infusion should be considered in these patients.10 During therapy, patients should be monitored for adverse events such as arrhythmias and hypotension. Many of these patients may be receiving concomitant IV furosemide or bumetanide, both of which are incompatible with milrinone.Dobutamine primarily exerts its cardiac effects via β1-adrenergic receptor activation. It has the potential to cause some peripheral vasodilation at higher doses (> 10 μg/kg per minute) by activating β2-adrenergic receptors.9 Physicians may prefer to use dobutamine when circumstances require inotropic support with minimal effects on blood pressure. Dobutamine is supplied in formulations of 250 mg/250 mL, 500 mg/250 mL, and 1000 mg/250 mL. The 250 mg/250 mL formulation is typically used for peripheral administration to avoid thrombophlebitis in patients without a central venous catheter. The concentrated 1000 mg/250 mL formulation must be given through a central venous catheter but is ideal for patients with heart failure who regularly require fluid restriction. Dobutamine, like milrinone, should be initiated at low doses (≤ 5 μg/kg per minute) and titrated to effect. Cardiac arrhythmias or tachycardia can occur during infusion.9 Because of the short half-life (2 minutes) of dobutamine, discontinuing or slowing the infusion may quickly resolve these issues. Hepatic or renal impairment does not prolong its half-life, and dosing adjustments are not needed in patients with these conditions.β-Blockers, angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), mineralocorticoid antagonists, and an angiotensin receptor–neprilysin inhibitor all have morbidity and mortality benefits in patients with HFrEF.25 Less is known about whether these medications provide a mortality benefit in patients with heart failure–preserved ejection fraction. These patients often are treated for underlying risk factors and comorbidities with goal-directed medical therapy similar to that of patients with HFrEF.25After patients with ADHF are stabilized, long-term therapies should be initiated or reinitiated prior to discharge and should continue on an outpatient basis. Initiation of a β-blocker and ACE inhibitor or ARB therapy is recommended after optimization of volume status. Administration should begin with low doses and titrated up gradually (every 1 to 2 weeks) to reduce the potential for adverse effects such as hypotension, bradycardia, and fatigue (with β-blockers) and hypotension, acute renal failure, and hyperkalemia (with ACE inhibitor or ARB therapy).25Bisoprolol, carvedilol, and metoprolol succinate are the only β-blockers with a proven mortality benefit in patients with HFrEF.25 These agents exert their therapeutic effects by blocking β1-adrenergic receptors to slow the progression of heart failure and reduce the effects of catecholamine stress on the heart. Bisoprolol and metoprolol are cardioselective, acting only on β1-adrenergic receptors. Carvedilol possesses antioxidant properties and acts on β2- and β1-adrenergic receptors to reduce vascular resistance. It does have the potential to exacerbate moderate to severe respiratory airway disease (eg, chronic obstructive pulmonary disease, asthma) because of its antagonistic effects on β2-adrenergic receptors. Additionally, it has the potential to reduce the effect of β2-adrenergic agonists (eg, albuterol) commonly used to treat airway diseases.26Angiotensin receptor blockers are typically second-line therapy for patients intolerant to treatment with an ACE inhibitor. These therapies are rarely used in combination because of the potential for harmful effects. Caution should be taken when initiating these agents in patients with hypotension (systolic blood pressure < 80 mm Hg), hyperkalemia (serum potassium level > 5 mEq/L), and poor renal function (serum creatinine level > 3 mg/dL).25 A combination medication containing both an ARB (valsartan) and an angiotensin receptor– neprilysin inhibitor (sacubitril) has recently been added to the guidelines to treat patients with reduced ejection fraction.25 The addition of sacubitril is thought to provide beneficial hemodynamic effects by increasing the levels of several endogenous vasoactive peptides.27Treatment of patients with ADHF is targeted to achieve an end goal of “warm and dry” (ie, Forrester hemodynamic subset I). Optimal use of diuretic, vasodilator, and inotropic therapies are beneficial in improving fluid status and end-organ perfusion. The Forrester hemodynamic subset table is useful in guiding initial pharmacotherapy. Continuous monitoring of clinical signs and symptoms directs further treatment. When hemodynamic stabilization of the patient is achieved, long-term treatment with a β-blocker and ACE inhibitor or ARB therapy should be initiated to reduce the risk of postdischarge mortality or readmission.
No takes yet. Share an insight, caveat, or question.
Priddy et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: